Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3559
Source ID: NCT01511172
Associated Drug: Liraglutide
Title: Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: liraglutide|DRUG: metformin|DRUG: placebo|DRUG: placebo|DRUG: glimepiride
Outcome Measures: Primary: Fasting plasma/serum glucose | Secondary: Home monitored fasting plasma glucose|Home monitored 7-point glucose profile|Fructosamine|Insulin|C-peptide|HbA1c (glycated haemoglobin A1c)|Weight|Beta-cell function and insulin resistance (HOMA model)|Gastro-intestinal adverse events|Other adverse events
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 145
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2002-08
Completion Date: 2002-12
Results First Posted:
Last Update Posted: 2017-01-25
Locations: Novo Nordisk Investigational Site, Daw Park, South Australia, 5041, Australia|Novo Nordisk Investigational Site, Adelaide, SA 5035, Australia|Novo Nordisk Investigational Site, Ashford, 5035, Australia|Novo Nordisk Investigational Site, Garran, 2605, Australia|Novo Nordisk Investigational Site, Wien, 1030, Austria|Novo Nordisk Investigational Site, Wien, A 1090, Austria|Novo Nordisk Investigational Site, Wien, A-1130, Austria|Novo Nordisk Investigational Site, Ceske Budejovice, 37001, Czech Republic|Novo Nordisk Investigational Site, Praha 10, 10034, Czech Republic|Novo Nordisk Investigational Site, Frederiksberg, 2000, Denmark|Novo Nordisk Investigational Site, København, 2400, Denmark|Novo Nordisk Investigational Site, Køge, 4600, Denmark|Novo Nordisk Investigational Site, Thisted, 7700, Denmark|Novo Nordisk Investigational Site, Århus C, 8000, Denmark|Novo Nordisk Investigational Site, LA ROCHELLE cedex, 17019, France|Novo Nordisk Investigational Site, Narbonne, 11108, France|Novo Nordisk Investigational Site, NEVERS cedex, 58033, France|Novo Nordisk Investigational Site, Paris Cedex 10, 75475, France|Novo Nordisk Investigational Site, Bad Lauterberg, 37431, Germany|Novo Nordisk Investigational Site, Berlin, 12203, Germany|Novo Nordisk Investigational Site, Bochum, 44791, Germany|Novo Nordisk Investigational Site, Freiburg, 79106, Germany|Novo Nordisk Investigational Site, Kaiserslautern, 67675, Germany|Novo Nordisk Investigational Site, Mannheim, 68167, Germany|Novo Nordisk Investigational Site, Neuss, 41460, Germany|Novo Nordisk Investigational Site, Rawa Mazowiecka, 96-200, Poland|Novo Nordisk Investigational Site, Zabrze, 41-800, Poland|Novo Nordisk Investigational Site, Addlestone, KT15 2BH, United Kingdom|Novo Nordisk Investigational Site, Aylesbury, HP21 7TL, United Kingdom|Novo Nordisk Investigational Site, Barnsley, S70 3RJ, United Kingdom|Novo Nordisk Investigational Site, Bexhill-on-Sea, TN39 4SP, United Kingdom|Novo Nordisk Investigational Site, Caerleon, NP18 1AZ, United Kingdom|Novo Nordisk Investigational Site, Camberley, GU15 2NN, United Kingdom|Novo Nordisk Investigational Site, Chippenham, SN15 1HP, United Kingdom|Novo Nordisk Investigational Site, East Horsley, KT24 6QT, United Kingdom|Novo Nordisk Investigational Site, Frome, BA11 1EZ, United Kingdom|Novo Nordisk Investigational Site, Magherafelt, United Kingdom|Novo Nordisk Investigational Site, Sheffield, S3 9DA, United Kingdom|Novo Nordisk Investigational Site, Soham, CB7 5JD, United Kingdom|Novo Nordisk Investigational Site, Sunbury on Thames, TW16 6RH, United Kingdom|Novo Nordisk Investigational Site, Yaxley. Peterborough, PE7 3JL, United Kingdom
URL: https://clinicaltrials.gov/show/NCT01511172

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D089 Metformin small molecule DB00331 Details